This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Treatment of Traumatic Hyphema With Topical -Aminocaproic Acid

Morton F. Goldberg, MD

Arch Ophthalmol. 1997;115(9):1189-1190.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE HOLY GRAIL in treatment of traumatic hyphema has been reduction in the rate of recurrent bleeding ("secondary hemorrhage"). Ample evidence exists that secondary hemorrhage is associated with a worsened visual prognosis in comparison with eyes not sustaining such events.^1,2 The cause of the reduced vision is frequently multifactorial; often, however, it can be directly attributable to the extra bleeding itself, because the induced glaucoma causes optic atrophy or corneal blood staining. In most therapeutic trials for traumatic hyphema, therefore, the key end-point variable has been the rate of secondary hemorrhage. During the past 20 years, several trials^3-6 have shown that this rate can be significantly reduced by use of a systemic (oral) antifibrinolytic agent, usually -aminocaproic acid (Amicar) or tranexamic acid. Topical and systemic corticosteroids have also had their proponents^7-9 and their detractors.¹⁰

Although several clinical trials with Amicar have shown a reduction in the . . . [Full Text PDF of this Article]

Author Affiliations
Baltimore, Md

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?